Listed

Lifecore Biomedical, Inc. \de\

LFCRNasdaqCIK 1005286HealthcareFiscal year ends May 25

Latest reported revenue, Q2 FY2027$34.2mRevenue, Q2 FY2027, three months to 2026-06-30$34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2027

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$34.2mRevenue, Q2 FY2027, three months to 2026-06-30$34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figureNo year-earlier figure to compare
  • Gross margin35.3%Gross margin, Q2 FY2027, three months to 2026-06-30. gross profit / revenueGross profit: $12.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figureNo year-earlier figure to compare
  • Operating margin7.5%Operating margin, Q2 FY2027, three months to 2026-06-30. operating income / revenueOperating income: $2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figureNo year-earlier figure to compare
  • Net margin−18.0%Net margin, Q2 FY2027, three months to 2026-06-30. net income / revenueNet income: −$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figureNo year-earlier figure to compare
  • Diluted EPS−$0.19Diluted EPS, Q2 FY2027, three months to 2026-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figureNo year-earlier figure to compare
  • Free cash flow−$2.7mFree cash flow, Q2 FY2027, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001005286-26-000033. Derived: 6-month figure less the 3-month figure.Capital expenditure: $513.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001005286-26-000033. Derived: 6-month figure less the 3-month figure.Report this figureNo year-earlier figure to compare

Last eight quarters

Full statements
Revenue$34.2mGross margin 35.3%
Diluted EPS−$0.19, Q2 FY2027
Free cash flow−$2.7m, Q2 FY2027
Lifecore Biomedical, Inc. \de\, key figures for the last eight quarters
Line itemUnitQ4 FY20242024-05-26Q1 FY20252024-08-25Q2 FY20252024-11-24Q3 FY20252025-02-23Q4 FY20252025-05-25Q1 FY20262025-09-30Q1 FY20262026-03-31Q2 FY20272026-06-30Shape over the periods
Revenue$m37.9Revenue, Q4 FY2024, three months to 2024-05-26$37.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure24.7Revenue, Q1 FY2025, three months to 2024-08-25$24.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure32.6Revenue, Q2 FY2025, three months to 2024-11-24$32.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Report this figure35.2Revenue, Q3 FY2025, three months to 2025-02-23$35.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure36.4Revenue, Q4 FY2025, three months to 2025-05-25$36.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure31.1Revenue, Q1 FY2026, three months to 2025-09-30$31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure23.2Revenue, Q1 FY2026, three months to 2026-03-31$23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure34.2Revenue, Q2 FY2027, three months to 2026-06-30$34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure
Gross margin%45.6%Gross margin, Q4 FY2024, three months to 2024-05-26. gross profit / revenueGross profit: $17.3m. XBRL concept us-gaap:GrossProfit. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $37.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure21.8%Gross margin, Q1 FY2025, three months to 2024-08-25. gross profit / revenueGross profit: $5.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Revenue: $24.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure34.0%Gross margin, Q2 FY2025, three months to 2024-11-24. gross profit / revenueGross profit: $11.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Revenue: $32.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Report this figure28.0%Gross margin, Q3 FY2025, three months to 2025-02-23. gross profit / revenueGross profit: $9.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Revenue: $35.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure38.4%Gross margin, Q4 FY2025, three months to 2025-05-25. gross profit / revenueGross profit: $14.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $36.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure25.0%Gross margin, Q1 FY2026, three months to 2025-09-30. gross profit / revenueGross profit: $7.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Revenue: $31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure19.2%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $4.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Revenue: $23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure35.3%Gross margin, Q2 FY2027, three months to 2026-06-30. gross profit / revenueGross profit: $12.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure
Operating margin%5.7%Operating margin, Q4 FY2024, three months to 2024-05-26. operating income / revenueOperating income: $2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $37.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(46.9%)Operating margin, Q1 FY2025, three months to 2024-08-25. operating income / revenueOperating income: −$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Revenue: $24.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(6.0%)Operating margin, Q2 FY2025, three months to 2024-11-24. operating income / revenueOperating income: −$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Revenue: $32.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Report this figure(25.7%)Operating margin, Q3 FY2025, three months to 2025-02-23. operating income / revenueOperating income: −$9.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Revenue: $35.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure14.6%Operating margin, Q4 FY2025, three months to 2025-05-25. operating income / revenueOperating income: $5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $36.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure(9.9%)Operating margin, Q1 FY2026, three months to 2025-09-30. operating income / revenueOperating income: −$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Revenue: $31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(20.1%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Revenue: $23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure7.5%Operating margin, Q2 FY2027, three months to 2026-06-30. operating income / revenueOperating income: $2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure
Net margin%(18.7%)Net margin, Q4 FY2024, three months to 2024-05-26. net income / revenueNet income: −$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Revenue: $37.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(65.7%)Net margin, Q1 FY2025, three months to 2024-08-25. net income / revenueNet income: −$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Revenue: $24.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(20.2%)Net margin, Q2 FY2025, three months to 2024-11-24. net income / revenueNet income: −$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Revenue: $32.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Report this figure(42.0%)Net margin, Q3 FY2025, three months to 2025-02-23. net income / revenueNet income: −$14.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Revenue: $35.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure(3.1%)Net margin, Q4 FY2025, three months to 2025-05-25. net income / revenueNet income: −$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $36.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure(32.1%)Net margin, Q1 FY2026, three months to 2025-09-30. net income / revenueNet income: −$10.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Revenue: $31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(64.6%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Revenue: $23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure(18.0%)Net margin, Q2 FY2027, three months to 2026-06-30. net income / revenueNet income: −$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Revenue: $34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(0.53)Diluted EPS, Q1 FY2025, three months to 2024-08-25−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(0.25)Diluted EPS, Q2 FY2025, three months to 2024-11-24−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-01-02, accession 0001005286-25-000012.Report this figure(0.42)Diluted EPS, Q3 FY2025, three months to 2025-02-23−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure(0.06)Diluted EPS, Q4 FY2025, three months to 2025-05-25−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure(0.29)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(0.43)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure(0.19)Diluted EPS, Q2 FY2027, three months to 2026-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001005286-26-000033.Report this figure
Free cash flow$m6.0Free cash flow, Q4 FY2024, three months to 2024-05-26. operating cash flow − capital expenditureOperating cash flow: $8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure(4.0)Free cash flow, Q1 FY2025, three months to 2024-08-25. operating cash flow − capital expenditureOperating cash flow: −$613.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Capital expenditure: $3.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure(8.6)Free cash flow, Q2 FY2025, three months to 2024-11-24. operating cash flow − capital expenditureOperating cash flow: −$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-01-02, accession 0001005286-25-000012. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-01-02, accession 0001005286-25-000012. Derived: 6-month figure less the 3-month figure.Report this figure(4.3)Free cash flow, Q3 FY2025, three months to 2025-02-23. operating cash flow − capital expenditureOperating cash flow: $1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Capital expenditure: $5.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure3.3Free cash flow, Q4 FY2025, three months to 2025-05-25. operating cash flow − capital expenditureOperating cash flow: $5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-KT filed 2026-03-16, accession 0001005286-26-000009. Derived: 12-month figure less the 9-month figure.Report this figure0.0Free cash flow, Q1 FY2026, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001005286-25-000148.Report this figure3.6Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001005286-26-000020.Report this figure(2.7)Free cash flow, Q2 FY2027, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001005286-26-000033. Derived: 6-month figure less the 3-month figure.Capital expenditure: $513.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001005286-26-000033. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$128.9mGross margin 31.3%
Diluted EPS−$1.27, FY2025
Free cash flow−$13.6m, FY2025
Lifecore Biomedical, Inc. \de\, key figures for the last five fiscal years
Line itemUnitFY20212021-05-30FY20222022-05-29FY20232023-05-28FY20242024-05-26FY20252025-05-25Shape over the periods
Revenue$m101Revenue, FY2021, twelve months to 2021-05-30$100.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-20, accession 0001005286-24-000030.Report this figure111Revenue, FY2022, twelve months to 2022-05-29$111.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure103Revenue, FY2023, twelve months to 2023-05-28$103.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure128Revenue, FY2024, twelve months to 2024-05-26$128.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure129Revenue, FY2025, twelve months to 2025-05-25$128.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure
Gross margin%38.6%Gross margin, FY2021, twelve months to 2021-05-30. gross profit / revenueGross profit: $38.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-20, accession 0001005286-24-000030.Revenue: $100.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-20, accession 0001005286-24-000030.Report this figure35.1%Gross margin, FY2022, twelve months to 2022-05-29. gross profit / revenueGross profit: $39.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-08-26, accession 0001005286-24-000124.Revenue: $111.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure27.1%Gross margin, FY2023, twelve months to 2023-05-28. gross profit / revenueGross profit: $28.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-08-26, accession 0001005286-24-000124.Revenue: $103.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure32.6%Gross margin, FY2024, twelve months to 2024-05-26. gross profit / revenueGross profit: $41.9m. XBRL concept us-gaap:GrossProfit. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Revenue: $128.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure31.3%Gross margin, FY2025, twelve months to 2025-05-25. gross profit / revenueGross profit: $40.3m. XBRL concept us-gaap:GrossProfit. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Revenue: $128.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure
Operating margin%(8.7%)Operating margin, FY2021, twelve months to 2021-05-30. operating income / revenueOperating income: −$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-20, accession 0001005286-24-000030.Revenue: $100.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-20, accession 0001005286-24-000030.Report this figure(10.6%)Operating margin, FY2022, twelve months to 2022-05-29. operating income / revenueOperating income: −$11.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-08-26, accession 0001005286-24-000124.Revenue: $111.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure(21.1%)Operating margin, FY2023, twelve months to 2023-05-28. operating income / revenueOperating income: −$21.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-08-26, accession 0001005286-24-000124.Revenue: $103.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure(6.9%)Operating margin, FY2024, twelve months to 2024-05-26. operating income / revenueOperating income: −$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Revenue: $128.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure(13.4%)Operating margin, FY2025, twelve months to 2025-05-25. operating income / revenueOperating income: −$17.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Revenue: $128.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure
Net margin%(32.0%)Net margin, FY2021, twelve months to 2021-05-30. net income / revenueNet income: −$32.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-20, accession 0001005286-24-000030.Revenue: $100.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-20, accession 0001005286-24-000030.Report this figure(104.9%)Net margin, FY2022, twelve months to 2022-05-29. net income / revenueNet income: −$116.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-08-26, accession 0001005286-24-000124.Revenue: $111.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure(96.4%)Net margin, FY2023, twelve months to 2023-05-28. net income / revenueNet income: −$99.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-08-26, accession 0001005286-24-000124.Revenue: $103.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure9.4%Net margin, FY2024, twelve months to 2024-05-26. net income / revenueNet income: $12.0m. XBRL concept us-gaap:NetIncomeLoss. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Revenue: $128.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure(30.0%)Net margin, FY2025, twelve months to 2025-05-25. net income / revenueNet income: −$38.7m. XBRL concept us-gaap:NetIncomeLoss. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Revenue: $128.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure
Diluted EPS$ per share(1.10)Diluted EPS, FY2021, twelve months to 2021-05-30−$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-20, accession 0001005286-24-000030.Report this figure(3.97)Diluted EPS, FY2022, twelve months to 2022-05-29−$3.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure(3.32)Diluted EPS, FY2023, twelve months to 2023-05-28−$3.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-08-26, accession 0001005286-24-000124.Report this figure0.33Diluted EPS, FY2024, twelve months to 2024-05-26$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure(1.27)Diluted EPS, FY2025, twelve months to 2025-05-25−$1.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure
Free cash flow$m(2.8)Free cash flow, FY2021, twelve months to 2021-05-30. operating cash flow − capital expenditureOperating cash flow: $16.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-20, accession 0001005286-24-000030.Capital expenditure: $19.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2023-03-16, accession 0001005286-23-000055.Report this figure(48.8)Free cash flow, FY2022, twelve months to 2022-05-29. operating cash flow − capital expenditureOperating cash flow: −$22.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-08-26, accession 0001005286-24-000124.Capital expenditure: $26.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2023-03-16, accession 0001005286-23-000055.Report this figurenot reported (Capital expenditure not reported)(18.1)Free cash flow, FY2024, twelve months to 2024-05-26. operating cash flow − capital expenditureOperating cash flow: $257.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Capital expenditure: $18.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure(13.6)Free cash flow, FY2025, twelve months to 2025-05-25. operating cash flow − capital expenditureOperating cash flow: −$206.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Capital expenditure: $13.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-KT filed 2026-03-16, accession 0001005286-26-000009.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Lifecore Biomedical, Inc. \de\
FundQuarter endedReported valueSharesPut or callChange on the quarter before
WYNNEFIELD CAPITAL INC2026-06-30$24.7m4,703,216Unchanged
Legion Partners Asset Management, LLC2026-06-30$23.4m4,461,823Unchanged
Greenhaven Road Investment Management, L.P.2026-06-30$16.8m3,190,769Reduced−346,804
325 CAPITAL LLC2026-06-30$15.2m2,895,881Added+733,415
BlackRock, Inc.2026-06-30$10.6m2,013,093Added+135,788
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$6.8m1,288,621Reduced−1,515
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$4.5m855,500Added+40,393
MORGAN STANLEY2026-06-30$4.0m769,360Added+4,626
STATE STREET CORP2026-06-30$3.5m668,031Added+26,025
Quinn Opportunity Partners LLC2026-06-30$2.4m453,495Unchanged

Recent filings

All 1,190 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Lifecore Biomedical, Inc. \de\, recent filings
FiledFormWhat it isAccession number
2026-10-2020:30 ET8-K8.01 Other events0001005286-26-000040
2026-09-2920:15 ETSCHEDULE 13D/AOwnership report, active investor, amended0001104659-26-111939
2026-09-2920:12 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001005286-26-000036
2026-09-2821:41 ETSCHEDULE 13D/AOwnership report, active investor, amended0000921895-26-002661
2026-09-2812:53 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-26-037767
2026-08-0511:20 ET10-QQuarterly reportPeriod 2026-06-300001005286-26-000033
2026-08-0511:17 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001005286-26-000032
2026-07-0221:36 ETSCHEDULE 13D/AOwnership report, active investor, amended0000921895-26-001747
2026-07-0221:17 ET8-K7.01 Regulation FD disclosure0001005286-26-000026
2026-07-0221:15 ETSCHEDULE 13D/AOwnership report, active investor, amended0001193125-26-294951

Latest annual report

Form 10-K for the fiscal year ended May 25, 2025Filed Aug 7, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1005286
Tickers
LFCR
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
May 25
Incorporated in
DE
Filer category
Accelerated filer<br>Smaller reporting company
Former names
LANDEC CORP \CA\ (to 2022-11-07)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. Listed shows no prices and gives no investment advice.